Articles tagged "Graft survival"

2017 American Transplant Congress
Recipient iNOS Deficiency Reduces Spontaneous Kidney Allograft Acceptance by Accelerating Allograft Loss.
I. Aljabban, B. Jiang, C. Yang, D. Ndishabandi, R. White, P. Russell, J. Madsen, R. Colvin, A. Alessandrini.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
Nitric oxide (NO) production by inducible nitric oxide synthase (iNOS), encoded by NOS2, is a hallmark of the innate immune axis, and is typically associated…
2017 American Transplant Congress
Effect of Initial Hepatic Arterial Followed by Portal Reperfusion on Outcomes After Liver Transplantation.
R. Shahbazov,¹ F. Azari,² J. Alejo,² M. Talanian,² M. Fox,² K. Kennedy,² S. Kessel,² A. Nickkholgh,¹ D. Maluf,¹ S. Pelletier.¹
¹Department of Surgery, University of Virginia Medical Center, Charlottesville, VA; ²University of Virginia School of Medicine, Charlottesville, VA
Background: While initial portal reperfusion (PV) of a liver allograft is nearly standardized, limited data suggests initial hepatic arterial reperfusion (HA) may improve hemodynamics and…
2017 American Transplant Congress
Three Induction Therapies on Patients with Delayed Graft Function After Kidney Transplantation, a Three-Year Outcome Analysis.
A. Umber, M. Killackey, A. Paramesh, B. Alper, F. Teran, A. Baudy, Y. Liu, J. Buell, R. Zhang.
Departments of Medicine and Surgery, Tulane University School of Medicine, New Orleans, LA
We compare the 3-year outcomes of induction therapies with either methylprednisolone (group 1, n=58), basiliximab (group 2, n=56) or alemtuzumab (group 3, n=98) in primary…
2017 American Transplant Congress
A Composite Score Associated with Spontaneous Operational Tolerance in Kidney Transplant Recipients.
R. Danger,¹ M. Chesneau,¹ C. Paul,¹ P. Guérif,¹ M. Durand,¹ K. Newell,² S. Kanaparthi,³ L. Turka,⁴ J.-P. Soulillou,¹ R. Houlgatte,⁵ M. Giral,^1,6 G. Ramstein,⁷ S. Brouard.^1,6
¹Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France; ²Department of Surgery, Emory University, Atlanta, GA; ³Immune Tolerance Network, Bethesda, MD; ⁴Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA; ⁵INSERM UMR 954,CHU de Nancy, DRCI, Nancy, France; ⁶CIC Biotherapy, CHU Nantes, Nantes, France; ⁷LINA DUKe, UMR 6241, Université de Nantes, Ecole des Mines de Nantes & CNRS, Nantes, France
New challenges in renal transplantation include using biological information to devise a useful clinical test for discerning high- and low-risk patients for individual therapy and…
2017 American Transplant Congress
Donor Creatinine and Graft Outcomes in Pediatric Kidney Transplant Recipients.
N. Hayde, M. Del Rio.
Montefiore Medical Center, Bronx, NY
Background: The role of donor peak and terminal creatinine on short and long term allograft outcomes in pediatric kidney transplant recipients is unclear.Aim: To determine…
2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; ³Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ⁴Renal Medicine, Monash Medical Centre, Melbourne, Australia; ⁵University of Queensland, Princess Alexandra Hospital, Queensland, Australia; ⁶Renal Medicine, Westmead Hospital, Sydney, Australia; ⁷WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; ⁸Novartis Pharmaceuticals, Sydney, Australia; ⁹Renal Medicine, Alfred Hospital, Melbourne, Australia.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
2016 American Transplant Congress
Impact of Simultaneous Pancreas-Kidney Transplantation versus Kidney Transplant Alone on Patient and Graft Survival in Type 2 Diabetics with Elevated BMI.
S. Singh,^1,2 S. Kim.^1,2,3,4
¹Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Canada; ²Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada; ³Division of Nephrology and the Multi-Organ Transplant Program, University Health Network, Toronto General Hospital, Toronto, Canada; ⁴Division of Nephrology and the Kidney Transplant Program, St. Michael's Hospital, Toronto, Canada.
Background: Simultaneous Pancreas-Kidney transplantation (SPKT) is becoming increasingly common in patients with Type 2 diabetes (T2DM). The BMI threshold for listing for SPKT in this…
2016 American Transplant Congress
Center and Surgeons' Experience Improves Outcome in Adult-to-Adult Living Donor Liver Transplantation: Validation of the Report of the A2ALL Consortium.
S. Nagai, A. Yoshida, M. Rizzari, K. Collins, D. Kim, M. Abouljoud.
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI.
Background: Adult-to-adult living donor liver transplantation cohort study (A2ALL) has reported improved outcomes in centers with greater experience (>20 cases). The aim of this study…
2016 American Transplant Congress
The Use of Kidney Donors Older Than 80 Years Does Not Affect Graft Survival in the Medium Term.
A. Fernández,¹ J. González,² C. Galeano,¹ S. Elias,¹ S. Jimenez,¹ F. Caravaca,¹ S. Pampa,¹ R. Marcen.¹
¹Nephrology, Hospital Ramón y Cajal, Madrid, Spain; ²Nephrology, Hospital de León, Leon, Spain.
INTRODUCTION:Kidney transplantation is the best option for renal replacement therapy. One of its main limitations is the organs shortage. We analyzed the results in kidney…
2016 American Transplant Congress
Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients.
B. Chopra, K. Sureshkumar.
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
Induction therapy improves outcomes in kidney transplant recipients (KTRs) by reducing early acute rejection. In the current era of potent maintenance immunosuppression, the role of…